Matches in SemOpenAlex for { <https://semopenalex.org/work/W2908584952> ?p ?o ?g. }
- W2908584952 endingPage "1712" @default.
- W2908584952 startingPage "1703" @default.
- W2908584952 abstract "Abstract Background The prognosis of advanced oral squamous cell carcinoma is poor. We investigated the effect of cetuximab‐based sequential therapy as a primary treatment. Methods Forty‐seven treatment‐naive patients with advanced tumors originating from the oral cavity or oropharynx were enrolled. Neoadjuvant cetuximab, paclitaxel, and cisplatin were administered, followed by cetuximab‐based radiotherapy. Immunohistochemical staining was applied to study the tissues. Results The best overall response rate was 70.2%, including 4 patients with a complete response and 29 with a partial response. The median progression‐free and overall survival rates were 10.3 and 15.2 months, respectively. Patients with more than 50% tumor reduction with neoadjuvant therapy had better survival outcomes. Twenty‐two patients had severe adverse events with mostly dermatological complications. Of the 16 patients who received operations, 9 had increased PD‐L1 staining compared to pretreatment biopsy in the post hoc study. Conclusion The regimen was effective in selected patients. Increased PD‐L1 suggested altered tumor features." @default.
- W2908584952 created "2019-01-25" @default.
- W2908584952 creator A5002509654 @default.
- W2908584952 creator A5015999780 @default.
- W2908584952 creator A5020328284 @default.
- W2908584952 creator A5027112485 @default.
- W2908584952 creator A5029280161 @default.
- W2908584952 creator A5062374856 @default.
- W2908584952 creator A5064923841 @default.
- W2908584952 creator A5065989323 @default.
- W2908584952 creator A5067404593 @default.
- W2908584952 creator A5074947569 @default.
- W2908584952 creator A5075207633 @default.
- W2908584952 date "2019-01-12" @default.
- W2908584952 modified "2023-10-01" @default.
- W2908584952 title "Sequential therapy of neoadjuvant biochemotherapy with cetuximab, paclitaxel, and cisplatin followed by cetuximab‐based concurrent bioradiotherapy in high‐risk locally advanced oral squamous cell carcinoma: Final analysis of a phase 2 clinical trial" @default.
- W2908584952 cites W1802303469 @default.
- W2908584952 cites W1963665993 @default.
- W2908584952 cites W1983970003 @default.
- W2908584952 cites W2020708595 @default.
- W2908584952 cites W2024571738 @default.
- W2908584952 cites W2027538916 @default.
- W2908584952 cites W2041058139 @default.
- W2908584952 cites W2045248401 @default.
- W2908584952 cites W2079315541 @default.
- W2908584952 cites W2096550186 @default.
- W2908584952 cites W2100088098 @default.
- W2908584952 cites W2103151974 @default.
- W2908584952 cites W2106787323 @default.
- W2908584952 cites W2112845420 @default.
- W2908584952 cites W2114073374 @default.
- W2908584952 cites W2120068217 @default.
- W2908584952 cites W2122035130 @default.
- W2908584952 cites W2122503228 @default.
- W2908584952 cites W2129707741 @default.
- W2908584952 cites W2137178561 @default.
- W2908584952 cites W2137759849 @default.
- W2908584952 cites W2139248078 @default.
- W2908584952 cites W2141274038 @default.
- W2908584952 cites W2141592118 @default.
- W2908584952 cites W2145078756 @default.
- W2908584952 cites W2152094258 @default.
- W2908584952 cites W2152609192 @default.
- W2908584952 cites W2154076860 @default.
- W2908584952 cites W2155384808 @default.
- W2908584952 cites W2157824687 @default.
- W2908584952 cites W2158776225 @default.
- W2908584952 cites W2159657105 @default.
- W2908584952 cites W2161649815 @default.
- W2908584952 cites W2166349420 @default.
- W2908584952 cites W2176647747 @default.
- W2908584952 cites W2177804157 @default.
- W2908584952 cites W2305656490 @default.
- W2908584952 cites W2340636398 @default.
- W2908584952 cites W2401455386 @default.
- W2908584952 cites W2406213538 @default.
- W2908584952 cites W2523194272 @default.
- W2908584952 cites W2529484692 @default.
- W2908584952 cites W2579647781 @default.
- W2908584952 cites W2591834340 @default.
- W2908584952 cites W2610858500 @default.
- W2908584952 cites W2625675763 @default.
- W2908584952 cites W2765183455 @default.
- W2908584952 cites W2766754072 @default.
- W2908584952 cites W2791311199 @default.
- W2908584952 cites W2794981178 @default.
- W2908584952 cites W2795727245 @default.
- W2908584952 doi "https://doi.org/10.1002/hed.25640" @default.
- W2908584952 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30636183" @default.
- W2908584952 hasPublicationYear "2019" @default.
- W2908584952 type Work @default.
- W2908584952 sameAs 2908584952 @default.
- W2908584952 citedByCount "12" @default.
- W2908584952 countsByYear W29085849522019 @default.
- W2908584952 countsByYear W29085849522020 @default.
- W2908584952 countsByYear W29085849522021 @default.
- W2908584952 countsByYear W29085849522022 @default.
- W2908584952 countsByYear W29085849522023 @default.
- W2908584952 crossrefType "journal-article" @default.
- W2908584952 hasAuthorship W2908584952A5002509654 @default.
- W2908584952 hasAuthorship W2908584952A5015999780 @default.
- W2908584952 hasAuthorship W2908584952A5020328284 @default.
- W2908584952 hasAuthorship W2908584952A5027112485 @default.
- W2908584952 hasAuthorship W2908584952A5029280161 @default.
- W2908584952 hasAuthorship W2908584952A5062374856 @default.
- W2908584952 hasAuthorship W2908584952A5064923841 @default.
- W2908584952 hasAuthorship W2908584952A5065989323 @default.
- W2908584952 hasAuthorship W2908584952A5067404593 @default.
- W2908584952 hasAuthorship W2908584952A5074947569 @default.
- W2908584952 hasAuthorship W2908584952A5075207633 @default.
- W2908584952 hasConcept C121608353 @default.
- W2908584952 hasConcept C126322002 @default.
- W2908584952 hasConcept C143998085 @default.
- W2908584952 hasConcept C2776694085 @default.
- W2908584952 hasConcept C2777292972 @default.
- W2908584952 hasConcept C2778239845 @default.
- W2908584952 hasConcept C2778292576 @default.
- W2908584952 hasConcept C2779998722 @default.